



PRECEPTORSHIP PROGRAMME

Lung Cancer

**ESMO
PRECEPTORSHIP**

**MANCHESTER
UNITED KINGDOM
1-3 MARCH 2023**

Co-Chairs

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Pilar Garrido López, Spain

ESMO-THE CHRISTIE PRECEPTORSHIP PROGRAMME LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

Manchester, United Kingdom

1-3 March 2023

CO-CHAIRS

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Pilar Garrido López, Spain

SPEAKERS

Andrea Ardizoni, Italy
Paul Baas, Netherlands
Haval Balata, United Kingdom
Neil Bayman, United Kingdom
Richard Booton, United Kingdom
Clara Chan, United Kingdom
Christopher Craig, United Kingdom
Simon Ekman, Sweden
Corinne Faivre-Finn, United Kingdom
Lizza Hendriks, Netherlands
Keith M. Kerr, United Kingdom
Jennifer A. King, United Kingdom
Rohit Kochhar, United Kingdom

Cécile Le Péchoux, France
Colin Lindsay, United Kingdom
Luis Paz-Ares, Spain
David Planchard, France
Martin Reck, Germany
Christina H. Ruhlmann, Denmark
Suresh Senan, Netherlands
Paul Taylor, United Kingdom
Fiona Thistlethwaite, United Kingdom
Paul E. Van Schil, Belgium
Giulia Veronesi, Italy
David Woolf, United Kingdom

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early-stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

ACCREDITATION

The programme of this event has been accredited with 16 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



Wednesday, 1 March 2023

08:15-09:15 60'	Registration	
09:15-09:25 10'	Welcome & Introduction	Fiona Blackhall, UK Raffaele Califano, UK Pilar Garrido López, ES
09:25-11:25 90'	SESSION 1 Screening and diagnostics for lung cancer	Co-Chairs: Raffaele Califano, UK Pilar Garrido López, ES
30'	Lung cancer screening: Pro and Contra	Haval Balata, UK
30'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
10:25-10:55	Coffee break	
30'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith M. Kerr, UK
11:25-12:25 60'	SESSION 1 - cont. Screening and diagnostics for lung cancer	Co-Chairs: Fiona Blackhall, UK Raffaele Califano, UK
30'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
30'	Diagnosis and management of malignant pleural effusion	Christopher Craig, UK
12:25-13:25	Lunch	
13:25-14:25 60'	SESSION 2 Radical treatment of early stage NSCLC	Co-Chairs: Cécile Le Péchoux, FR Giulia Veronesi, IT
30'	Surgery for early stage NSCLC	Giulia Veronesi, IT
30'	Stereotactic ablative RT for early stage NSCLC	Suresh Senan, NL
14:25-14:55	Coffee break	
14:55-15:55 60'	SESSION 2 - cont. Radical treatment of early stage NSCLC	Co-Chairs: Cécile Le Péchoux, FR Giulia Veronesi, IT
30'	Adjuvant radiotherapy for completely resected early-stage NSCLC	Cecile Le Péchoux, FR
30'	Adjuvant systemic therapies for resected early-stage NSCLC	Paul Taylor, UK
15:55-16:05 10'	Close of day 1	Fiona Blackhall, UK Raffaele Califano, UK Pilar Garrido López, ES

Thursday, 2 March 2023

09:00-12:30 180'	SESSION 3 Advanced NSCLC	Co-Chairs: Fiona Blackhall, UK Martin Reck, DE
30'	1 st line Immune-checkpoint blockade for advanced NSCLC	Luis Paz-Ares, ES
30'	1 st line chemotherapy for advanced NSCLC	David Planchard, FR
30'	2 nd line treatment for advanced NSCLC	Martin Reck, DE
10:30-11:00	Coffee break	
30'	Treatment of EGFR mutant advanced NSCLC	Raffaele Califano, UK
30'	Treatment of ALK and ROS1 positive advanced NSCLC	Fiona Blackhall, UK
30'	Treatment of KRAS mutant advanced NSCLC	Colin Lindsay, UK
12:30-13:30	Lunch	
13:30-15:00 90'	SESSION 4 Palliative treatment of lung cancer and mesothelioma	Co-Chairs: Lizza Hendriks, NL Simon Ekman, SE
30'	Beyond EGFR, ALK, ROS1 and KRAS: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
30'	Treatment of oligometastatic NSCLC	Lizza Hendriks, NL
30'	Systemic treatment of mesothelioma	Paul Baas, NL
15:00-15:30	Coffee break	
15:30-16:30 60'	SESSION 4 - cont. Palliative treatment of lung cancer and mesothelioma	Co-Chairs: Jennifer A. King, UK Christina H. Ruhlmann, DK
30'	Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach	Jennifer A. King, UK
30'	Supportive and palliative care in lung cancer	Christina H. Ruhlmann, DK
16:30-16:40 10'	Close of day 2	Fiona Blackhall, UK Raffaele Califano, UK Pilar Garrido López, ES
19:00	Welcome drink	
19:30	Dinner	

Friday, 3 March 2023

09:00-12:00 150'	SESSION 5 Locally advanced NSCLC	Co-Chairs: Clara Chan, UK Paul E. Van Schil, BE
30'	Treatment of locally advanced NSCLC in the elderly	David Woolf, UK
30'	Combined modality treatment for NSCLC with N2 disease	Clara Chan, UK
30'	Role of surgery for N2 disease	Paul E. Van Schil, BE
10:30-11:00	Coffee break	
60'	Participants clinical case discussion (3x20')	Faculty

Each 20 min slot for clinical case discussion includes 10' case presentation and 10' Q&A / interactive panel discussion

12:00-13:00	Lunch	
--------------------	--------------	--

13:00-14:30 90'	SESSION 6 SCLC	Co-Chairs: Corinne Faivre-Finn, UK Pilar Garrido López, ES
30'	Treatment of limited stage SCLC	Corinne Faivre-Finn, UK
30'	Chemotherapy for extensive stage SCLC	Andrea Ardizzoni, IT
30'	Immune checkpoint blockade for SCLC	Pilar Garrido López, ES

14:30-15:00	Coffee break	
--------------------	---------------------	--

15:00-16:30 90'	SESSION 6 - cont. SCLC	Co-Chairs: Fiona Blackhall, UK Raffaele Califano, UK
30'	Targeted agents in SCLC	Pilar Garrido López, ES
30'	Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC	Neil Bayman, UK
30'	CAR-T and next generation cell therapies for lung cancer	Fiona Thistlethwaite, UK

16:30-16:35 5'	Conclusion and farewell	Fiona Blackhall, UK Raffaele Califano, UK Pilar Garrido López, ES
--------------------------	--------------------------------	--

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org

